J&J's Stelara succeeds in chronic bowel disease study

 Johnson & Johnson said on Tuesday its blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial.

Two doses of Stelara, already approved for psoriasis, psoriatic arthritis and Crohn's disease, was tested in 961 patients with moderate-to-severe ulcerative colitis (UC) who had failed prior therapy.